QLS 101
Alternative Names: QLS-101Latest Information Update: 03 Apr 2023
Price :
$50 *
At a glance
- Originator University of Minnesota
- Developer Qlaris Bio
- Class Antiglaucomas
- Mechanism of Action KATP channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma; Low tension glaucoma; Open-angle glaucoma
Most Recent Events
- 20 Mar 2023 Qlaris Bio completes a phase II trial in Glaucoma (In adults, In children, In adolescents) in USA (Ophthalmic) (NCT05495269)
- 26 Aug 2022 Qlaris Bio completes a phase II trial in Low-tension-glaucoma in USA (Ophthalmic) (NCT04857827)
- 10 Aug 2022 Qlaris Bio plans a phase II trial for Glaucoma (In adults, In children, In adolescent) (Ophthalmic, Liquid) in September 2022 (NCT05495269)